BioNTech SE Statistics
Total Valuation
BioNTech SE has a market cap or net worth of $21.58 billion. The enterprise value is $6.44 billion.
| Market Cap | 21.58B |
| Enterprise Value | 6.44B |
Important Dates
The last earnings date was Tuesday, November 3, 2026, before market open.
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BioNTech SE has 247.93 million shares outstanding. The number of shares has increased by 4.29% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 247.93M |
| Shares Change (YoY) | +4.29% |
| Shares Change (QoQ) | -0.23% |
| Owned by Insiders (%) | 16.22% |
| Owned by Institutions (%) | 19.87% |
| Float | 106.00M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.75 |
| Forward PS | 11.89 |
| PB Ratio | 1.06 |
| P/TBV Ratio | 1.16 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.23 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.55, with a Debt / Equity ratio of 0.02.
| Current Ratio | 8.55 |
| Quick Ratio | 7.91 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -92.55 |
Financial Efficiency
Return on equity (ROE) is -8.14% and return on invested capital (ROIC) is -29.88%.
| Return on Equity (ROE) | -8.14% |
| Return on Assets (ROA) | -4.04% |
| Return on Invested Capital (ROIC) | -29.88% |
| Return on Capital Employed (ROCE) | -7.32% |
| Weighted Average Cost of Capital (WACC) | 11.41% |
| Revenue Per Employee | $352,052 |
| Profits Per Employee | -$214,288 |
| Employee Count | 7,807 |
| Asset Turnover | 0.12 |
| Inventory Turnover | 3.88 |
Taxes
In the past 12 months, BioNTech SE has paid $46.56 million in taxes.
| Income Tax | 46.56M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -15.65% in the last 52 weeks. The beta is 1.33, so BioNTech SE's price volatility has been higher than the market average.
| Beta (5Y) | 1.33 |
| 52-Week Price Change | -15.65% |
| 50-Day Moving Average | 94.66 |
| 200-Day Moving Average | 96.50 |
| Relative Strength Index (RSI) | 42.79 |
| Average Volume (20 Days) | 1,108,965 |
Short Selling Information
The latest short interest is 2.27 million, so 3.58% of the outstanding shares have been sold short.
| Short Interest | 2.27M |
| Short Previous Month | 2.50M |
| Short % of Shares Out | 3.58% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.35 |
Income Statement
In the last 12 months, BioNTech SE had revenue of $2.75 billion and -$1.67 billion in losses. Loss per share was -$6.68.
| Revenue | 2.75B |
| Gross Profit | 2.11B |
| Operating Income | -1.52B |
| Pretax Income | -1.63B |
| Net Income | -1.67B |
| EBITDA | -1.15B |
| EBIT | -1.52B |
| Loss Per Share | -$6.68 |
Balance Sheet
The company has $15.55 billion in cash and $408.59 million in debt, with a net cash position of $15.15 billion or $61.09 per share.
| Cash & Cash Equivalents | 15.55B |
| Total Debt | 408.59M |
| Net Cash | 15.15B |
| Net Cash Per Share | $61.09 |
| Equity (Book Value) | 20.11B |
| Book Value Per Share | 81.13 |
| Working Capital | 15.72B |
Cash Flow
In the last 12 months, operating cash flow was -$257.77 million and capital expenditures -$232.53 million, giving a free cash flow of -$490.30 million.
| Operating Cash Flow | -257.77M |
| Capital Expenditures | -232.53M |
| Depreciation & Amortization | 363.76M |
| Net Borrowing | 85.44M |
| Free Cash Flow | -490.30M |
| FCF Per Share | -$1.98 |
Margins
Gross margin is 76.73%, with operating and profit margins of -55.45% and -60.87%.
| Gross Margin | 76.73% |
| Operating Margin | -55.45% |
| Pretax Margin | -59.17% |
| Profit Margin | -60.87% |
| EBITDA Margin | -41.99% |
| EBIT Margin | -55.45% |
| FCF Margin | n/a |
Dividends & Yields
BioNTech SE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -4.29% |
| Shareholder Yield | -4.29% |
| Earnings Yield | -7.68% |
| FCF Yield | -2.30% |
Analyst Forecast
The average price target for BioNTech SE is $114.80, which is 31.88% higher than the current price. The consensus rating is "Buy".
| Price Target | $114.80 |
| Price Target Difference | 31.88% |
| Analyst Consensus | Buy |
| Analyst Count | 21 |
| Revenue Growth Forecast (3Y) | -7.12% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioNTech SE has an Altman Z-Score of 7.02 and a Piotroski F-Score of 2.
| Altman Z-Score | 7.02 |
| Piotroski F-Score | 2 |